Search | DIAL.pr - BOREAL

Accès à distance ? S'identifier sur le proxy UCLouvain

Displaying 2 results.

- Speech
Rituximab given after high dose therapy and autologous stem cell transplantation induces durable clearance of minimal residual disease in about half of the patients with follicular non Hodgkin's lymphoma: 36 months results of a multicenter open label phase II trial (M39012 trial).
Morschhauser, F. Recher, C. Milpied, N. Gressin, R Salles, G. Brice, P. Vey, N Haioun, C. Colombat, P Bourhis, JH Rossi, JF Berriot-Varoqueaux, N Bergougnoux, L Bosly, André[UCL] Delsol, G. Attal, M. (2004) 46th Annual Meeting of the American-Society-of-Hematology — San Diego(Ca)
- Journal article
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CRI): an intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial
Suciu, Stefan[UCL] Mandelli, F. de Witte, T. Zittoun, R Gallo, E Labar, B. De Rosa, G Belhabri, A Giustolisi, R Delarue, R. Liso, V Mirto, S Leone, G. Bourhis, JH Fioritoni, G Jehn, U. Amadori, S. Fazi, P. Hagemeijer, Anne[UCL] Willemze, R. (2003) Blood — Vol. 102, no. 4, p. 1232-1240 (2003)